Guru Subramanian Guru Murthy, MD
Hematology & Oncology · Milwaukee, WINPI 1104172329
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,670 of the $113,473 with a category attached, or 60.5%. 21 manufacturers reported payments, led by Amgen at 25.1% of the total. 2025 is the largest year on record at $41,766, more than ten times the $567 reported in 2021. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $623.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$28K
- Gilead$24K
- Rigel Pharmaceuticals, Inc.$21K
- Daiichi Sankyo Inc.$7K
- Servier Pharmaceuticals LLC$6K
- AstraZeneca$5K
- plus $22K from 15 others
Across 342 payments — averaging $20,658 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$2.6M
- Beone Medicines Ltd.$2.1M
- AstraZeneca$820K
- Daiichi Sankyo Inc.$398K
- Eli Lilly$264K
- Gilead$230K
- plus $636K from 6 others
What the payments were for
- Consulting fees$68,67061%
- Speaking & faculty fees$25,35522%
- Travel & lodging$13,82912%
- Food & beverage$5,6195%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $28,450 |
| Gilead(2 entities) | 28 | $24,078 |
| Rigel Pharmaceuticals, Inc. | 32 | $20,548 |
| Daiichi Sankyo Inc. | 11 | $7,390 |
| Servier Pharmaceuticals LLC | 10 | $6,008 |
| AstraZeneca | 3 | $4,500 |
| Pfizer | 5 | $3,481 |
| Beigene USA, Inc. | 11 | $3,408 |
| Syndax Pharmaceuticals, Inc. | 5 | $3,396 |
| Bristol Myers Squibb | 8 | $3,068 |
| Geron Corporation | 5 | $2,692 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,372 |
| Stemline Therapeutics Inc. | 2 | $1,905 |
| Adaptive Biotechnologies Corporation | 9 | $678 |
| Astellas Pharma US Inc | 1 | $500 |
| Genmab U.S., Inc. | 6 | $385 |
| Beone Medicines USA, Inc. | 3 | $296 |
| Astrazeneca UK Limited | 2 | $135 |
| Blueprint Medicines Corporation | 1 | $71 |
| AbbVie | 3 | $68 |
| Janssen Scientific Affairs, LLC | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,473 in reported general payments places this provider in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 26 | $536,990 |
| CalquenceAcalabrutinib Maleate | 19 | $203,483 |
| SprycelDasatinib | 17 | $113,182 |
| VenclextaVenetoclax | 30 | $102,741 |
| Posaconazole | 11 | $15,427 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $1,564 |
| Acyclovir | 28 | $442 |
| Levofloxacin | 11 | $250 |
| Ondansetron Hcl | 26 | $236 |
| Allopurinol | 12 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $4,500 | $203,48319 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $2,372 | $113,18217 claims |
| AbbVieVenclexta | $68 | $102,74130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in Milwaukee
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
- Renju Vechurettu RajMilwaukee$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.